NCT01050790 · OUTCOME

Complete Response Rate at 6 Months

Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma · Source last updated 2018-06-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

What was measured

16 of 17 patients proceeded to transplant. 6 month CR rate post transplant was 8/16 (50%).

Analysis population: 1 patient did not proceed to transplant.

azacitidine: 75 mg/sq m daily for 5 days lenalidomide: 10 mg p.o. daily, Days 6-21

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
5-azacytidine + Lenalidomide -> Auto Stem Cell Transplant	16

Source class 1

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
5-azacytidine + Lenalidomide -> Auto Stem Cell Transplant	50	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

denoms

description

16 of 17 patients proceeded to transplant. 6 month CR rate post transplant was 8/16 (50%).

groups

param Type

NUMBER

population Description

1 patient did not proceed to transplant.

reporting Status

POSTED

time Frame

6 months

title

Complete Response Rate at 6 Months

type

SECONDARY

unit Of Measure

percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice